1. An early-stage Kite Pharma, but applying T-cell therapies to a broader range of diseases beyond cancer, including viral infections like COVID-19.

2. Similar to a developing Gilead Sciences, but focused on T-cell therapeutics for conditions like acute COVID-19 and long COVID, as well as oncology.

• TVGN 489: An investigational precision T cell therapeutic designed to treat acute-risk COVID-19 patients and a subset of long COVID patients.
• Off-the-shelf precision T cell therapeutics: These are advanced cellular therapies developed across virology, oncology, and neurology.

Tevogen Bio Holdings Inc. (TVGN) is a clinical-stage biotechnology company. This means the company is currently focused on the research, development, and clinical trials of its investigational products, such as TVGN 489. As of its current stage, Tevogen does not have any commercial products approved for sale and therefore does not have major commercial customers. Its primary activities involve clinical research and development rather than product sales.

• ICON plc (ICLR)
• WuXi Advanced Therapies (WXATF)

Ryan Saadi, M.D., M.P.H. Chief Executive Officer and Founder

Dr. Ryan Saadi is the founder of Tevogen Bio, established in 2020. He brings nearly three decades of experience in healthcare, having held leadership roles in hospital administration, managed care, and life sciences. His career includes senior positions in market access, health policy, clinical development, and research at prominent organizations such as Janssen (Johnson & Johnson), CSL Behring, and Sanofi Genzyme.

Kirti Desai, CPA Chief Financial Officer

Kirti Desai serves as the Chief Financial Officer of Tevogen Bio.

Neal Flomenberg, M.D. Chief Scientific Officer and R&D Lead

Dr. Neal Flomenberg is the Chief Scientific Officer and R&D Lead at Tevogen Bio.

Sadiq Khan, MBA Chief Commercial Officer and Interim Head of Tevogen Generics

Sadiq Khan holds the position of Chief Commercial Officer and Interim Head of Tevogen Generics.

Stephen Chen, MBA Chief Technical Officer

Stephen Chen serves as the Chief Technical Officer.

The key risks for Tevogen Bio Holdings Inc. (TVGN) are primarily concentrated around its financial stability, the inherent challenges of clinical-stage drug development, and the evolving market landscape for its lead product.

1. Financial Viability and Liquidity: Tevogen operates as a pre-revenue, clinical-stage company with a history of sustained losses and ongoing cash burn, indicating a weak financial position. The company's ability to maintain operations and fund its essential clinical trials is heavily dependent on securing significant external financing, which carries a substantial risk of further shareholder dilution. Furthermore, Tevogen has received notices from Nasdaq regarding non-compliance with minimum market value and bid price requirements, raising concerns about potential delisting. Analytics also indicate a high probability of the company facing financial distress in the near future.
2. Clinical Development and Regulatory Approval Risks: As a biotechnology company, Tevogen's success hinges entirely on the successful progression of its investigational precision T-cell therapies, particularly TVGN-489, through rigorous clinical trials and ultimately obtaining regulatory approvals. Failures or significant delays at any stage of clinical development, or an inability to secure necessary regulatory endorsements, would severely jeopardize its business model and investment.
3. Market Acceptance and Competition for COVID-19 Therapeutics: Tevogen's lead product, TVGN-489, targets acute-risk COVID-19 patients and those with long COVID. The market for COVID-19 treatments is dynamic and highly competitive, with numerous existing therapies and vaccines. The demand and urgency for new COVID-19 specific therapies are continually evolving, which could impact the commercial viability and market acceptance of TVGN-489, even if it achieves regulatory approval.

Tevogen Bio Holdings Inc. (TVGN) operates in the biotechnology sector, developing precision T cell therapeutics. Its lead investigational product, TVGN 489, targets acute-risk COVID-19 patients and individuals suffering from long COVID.

The addressable markets for Tevogen's main products and services are significant:

• For **Long COVID therapeutics**, the global market was valued at approximately USD 3.8 billion in 2025 and is projected to reach USD 18.05 billion by 2034, growing at a compound annual growth rate (CAGR) of 18.9%. North America is a leading region in this market, accounting for approximately USD 1.5 billion in 2025. Another report indicates the global Long COVID Syndrome Market was valued at USD 3.2 billion in 2023 and is projected to experience substantial growth to USD 32.8 billion by 2031, with a 34.7% CAGR.
• For **acute-risk COVID-19 patients**, which falls under the broader severe acute respiratory syndrome coronavirus infection market, the market across the seven major markets (United States, EU4, United Kingdom, and Japan) reached USD 23.8 billion in 2024 and is expected to grow to USD 77.0 billion by 2035, exhibiting a CAGR of 11.29% during 2025-2035. The United States holds the largest patient pool and market for this treatment. Furthermore, the global COVID-19 Treatment market was valued at US$ 42.47 billion in 2025 and is expected to reach US$ 112.97 billion by 2034. The global COVID-19 Infection market was valued at USD 30.25 billion in 2025 and is expected to reach USD 79.28 billion by 2033, with North America dominating in revenue share.

Tevogen Bio Holdings Inc. (TVGN) anticipates several key drivers of future revenue growth over the next 2-3 years, primarily stemming from the advancement and commercialization of its diverse pipeline and strategic business expansion:

1. Launch of Oncology Pipeline Products: Tevogen projects significant revenue from its oncology pipeline, with a top-line forecast of $1 billion in the launch year and a cumulative 5-year estimate ranging from $10 billion to $14 billion. This includes product candidates such as TVGN 489 for SARS-CoV-2 infection in cancer patients, TVGN 920 for cervical cancer prevention, TVGN 930 for EBV-associated lymphomas, and TVGN 960 for mouth and throat cancer.
2. Commercialization of Specialty Care Pipeline Products: The company forecasts nearly $1 billion in revenue in the launch year for its specialty care pipeline, with a cumulative 5-year estimate between $18 billion and $22 billion. This pipeline includes TVGN 489, which is designed to address the unmet needs of acute-risk COVID-19 patients and those suffering from long COVID, as well as for SARS-CoV-2 infection in patients undergoing treatment for rheumatoid arthritis and psoriatic arthritis.
3. Introduction of TVGN 116 for Liver Cancer Prevention: Tevogen has estimated a cumulative 5-year top-line revenue forecast of approximately $6.5 billion for its product candidate TVGN 116, which is focused on preventing liver cancer in individuals with high-risk chronic Hepatitis B infections.
4. Strategic Acquisitions and Expansion into Healthcare Services: Tevogen is actively pursuing strategic acquisition initiatives, including a contract research organization (CRO) and other healthcare services, aimed at building a financially self-sufficient enterprise. If completed, these acquisitions could contribute approximately $100 million in combined annual revenue.
5. Leveraging the ExacTcell™ Platform and PredicTcell™ AI Technology: The company's unique, faster, and cost-efficient drug development model, underpinned by its proprietary ExacTcell™ platform and PredicTcell™ AI technology, is expected to accelerate target prediction, shorten development timelines, and improve treatment accessibility. This technological advantage is a foundational driver that enables the efficient progression and commercialization of its therapeutic pipeline, thus supporting overall revenue growth.

Share Issuance

• Tevogen Bio Holdings Inc. went public on February 15, 2024, when its common stock and public warrants began trading on Nasdaq, following a business combination.
• In August 2024, a prospectus outlined the potential issuance of up to 17,974,978 shares of common stock upon the exercise of outstanding warrants, and the resale of up to 24,551,308 shares of Common Stock and 725,000 outstanding warrants by securityholders. The company could receive up to approximately $207 million from the cash exercise of these warrants, each with an exercise price of $11.50.
• As of November 12, 2025, the company had an at-the-market (ATM) Sales Agreement for $50,000,000, through which it received net proceeds of $3.9 million.

Inbound Investments

• Tevogen Bio Holdings Inc. has raised a total of under $42 million in cash since its inception to June 30, 2025.
• On May 12, 2026, the company announced a $3 million private investment from The Patel Family, LLP, through the issuance of 375,000 prefunded warrants at an issue price of $8 per warrant.
• As of November 2025, the company's liquidity sources included a related-party Loan Agreement with $4,400,000 outstanding and $21,000,000 remaining capacity, and KRHP grants totaling $3.0 million year-to-date with an additional $7.0 million committed.

Capital Expenditures

• In the last 12 months, as of July 8, 2026, Tevogen Bio Holdings Inc.'s capital expenditures amounted to -$64,439.
• The company spent $64.44K on capital expenditures in the most recent reported quarter.